JP2008542428A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008542428A5 JP2008542428A5 JP2008515199A JP2008515199A JP2008542428A5 JP 2008542428 A5 JP2008542428 A5 JP 2008542428A5 JP 2008515199 A JP2008515199 A JP 2008515199A JP 2008515199 A JP2008515199 A JP 2008515199A JP 2008542428 A5 JP2008542428 A5 JP 2008542428A5
- Authority
- JP
- Japan
- Prior art keywords
- indol
- compound
- bis
- acid hydroxyamide
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000024245 cell differentiation Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 125000003147 glycosyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 229930002330 retinoic acid Natural products 0.000 claims 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical group C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000006681 (C2-C10) alkylene group Chemical group 0.000 claims 1
- WOXWAGCBPDSRPN-UHFFFAOYSA-N 3-[4-[bis(1h-indol-3-yl)methyl]phenyl]-n-hydroxyprop-2-enamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1C(C=1C2=CC=CC=C2NC=1)C1=CNC2=CC=CC=C12 WOXWAGCBPDSRPN-UHFFFAOYSA-N 0.000 claims 1
- XOABRVOPAZJQCU-UHFFFAOYSA-N 7,7-bis(1h-indol-3-yl)heptanoic acid Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)CCCCCC(=O)O)=CNC2=C1 XOABRVOPAZJQCU-UHFFFAOYSA-N 0.000 claims 1
- ZALBCDKLQFUZNN-UHFFFAOYSA-N 7,7-bis(4-fluoro-1h-indol-3-yl)-n-hydroxyheptanamide Chemical compound C1=CC(F)=C2C(C(C=3C4=C(F)C=CC=C4NC=3)CCCCCC(=O)NO)=CNC2=C1 ZALBCDKLQFUZNN-UHFFFAOYSA-N 0.000 claims 1
- OUOXATPGCGZWAK-UHFFFAOYSA-N 7,7-bis(7-ethyl-1h-indol-3-yl)-n-hydroxyheptanamide Chemical compound C1=CC=C2C(C(CCCCCC(=O)NO)C=3C=4C=CC=C(C=4NC=3)CC)=CNC2=C1CC OUOXATPGCGZWAK-UHFFFAOYSA-N 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010059866 Drug resistance Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000002475 indoles Chemical class 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 238000009830 intercalation Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- DJVHYWLVIXMHKA-UHFFFAOYSA-N n-hydroxy-4,4-bis(1h-indol-3-yl)butanamide Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)CCC(=O)NO)=CNC2=C1 DJVHYWLVIXMHKA-UHFFFAOYSA-N 0.000 claims 1
- UNKOKDUSFRTJQV-UHFFFAOYSA-N n-hydroxy-5,5-bis(1h-indol-3-yl)pentanamide Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)CCCC(=O)NO)=CNC2=C1 UNKOKDUSFRTJQV-UHFFFAOYSA-N 0.000 claims 1
- JAKKVYLKVYJELP-UHFFFAOYSA-N n-hydroxy-6,6-bis(1h-indol-3-yl)hexanamide Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)CCCCC(=O)NO)=CNC2=C1 JAKKVYLKVYJELP-UHFFFAOYSA-N 0.000 claims 1
- AMCCNRABUUCWIM-UHFFFAOYSA-N n-hydroxy-6-(1h-indol-3-yl)hexanamide Chemical compound C1=CC=C2C(CCCCCC(=O)NO)=CNC2=C1 AMCCNRABUUCWIM-UHFFFAOYSA-N 0.000 claims 1
- ZWBFOQJCRGCPED-UHFFFAOYSA-N n-hydroxy-7,7-bis(1h-indol-3-yl)heptanamide Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)CCCCCC(=O)NO)=CNC2=C1 ZWBFOQJCRGCPED-UHFFFAOYSA-N 0.000 claims 1
- OGZQMWDPHWVYAK-UHFFFAOYSA-N n-hydroxy-7,7-bis(5-methyl-1h-indol-3-yl)heptanamide Chemical compound C1=C(C)C=C2C(C(CCCCCC(=O)NO)C3=CNC4=CC=C(C=C43)C)=CNC2=C1 OGZQMWDPHWVYAK-UHFFFAOYSA-N 0.000 claims 1
- FSLXJUDEBBIVKO-UHFFFAOYSA-N n-hydroxy-7,7-bis(7-methoxy-1h-indol-3-yl)heptanamide Chemical compound C1=CC=C2C(C(CCCCCC(=O)NO)C=3C=4C=CC=C(C=4NC=3)OC)=CNC2=C1OC FSLXJUDEBBIVKO-UHFFFAOYSA-N 0.000 claims 1
- XVEQQXYYEHWLBU-UHFFFAOYSA-N n-hydroxy-7,7-bis[5-(morpholin-4-ylmethyl)-3h-indol-3-yl]heptanamide Chemical compound C1=NC2=CC=C(CN3CCOCC3)C=C2C1C(CCCCCC(=O)NO)C(C1=C2)C=NC1=CC=C2CN1CCOCC1 XVEQQXYYEHWLBU-UHFFFAOYSA-N 0.000 claims 1
- YRBZDDSKSDEOKC-UHFFFAOYSA-N n-hydroxy-7-(1h-indol-2-yl)-7-(1h-indol-3-yl)heptanamide Chemical compound C1=CC=C2C(C(C=3NC4=CC=CC=C4C=3)CCCCCC(=O)NO)=CNC2=C1 YRBZDDSKSDEOKC-UHFFFAOYSA-N 0.000 claims 1
- QNHLDXNWBDOXOP-UHFFFAOYSA-N n-hydroxy-8,8-bis(1h-indol-3-yl)octanamide Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)CCCCCCC(=O)NO)=CNC2=C1 QNHLDXNWBDOXOP-UHFFFAOYSA-N 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05012562 | 2005-06-10 | ||
| PCT/EP2006/062798 WO2006131484A1 (en) | 2005-06-10 | 2006-05-31 | Indole derivatives having antitumor activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008542428A JP2008542428A (ja) | 2008-11-27 |
| JP2008542428A5 true JP2008542428A5 (enExample) | 2009-07-16 |
Family
ID=35062959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008515199A Withdrawn JP2008542428A (ja) | 2005-06-10 | 2006-05-31 | 抗腫瘍活性を有するインドール誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8053460B2 (enExample) |
| EP (1) | EP1891007A1 (enExample) |
| JP (1) | JP2008542428A (enExample) |
| KR (1) | KR20080029967A (enExample) |
| CN (1) | CN101193861A (enExample) |
| AR (1) | AR053891A1 (enExample) |
| AU (1) | AU2006256771A1 (enExample) |
| BR (1) | BRPI0612542A2 (enExample) |
| CA (1) | CA2607337A1 (enExample) |
| EA (1) | EA013542B1 (enExample) |
| MX (1) | MX2007015274A (enExample) |
| TW (1) | TW200716545A (enExample) |
| WO (1) | WO2006131484A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2650810T3 (es) * | 2009-01-28 | 2018-01-22 | Karus Therapeutics Limited | Isósteros de Scriptaid y su uso en terapia |
| TWI429628B (zh) * | 2010-03-29 | 2014-03-11 | Univ Taipei Medical | 吲哚基或吲哚啉基羥肟酸化合物 |
| MX364295B (es) * | 2012-11-07 | 2019-04-22 | Karus Therapeutics Ltd | Inhibidores de histona desacetilasa novedosos y su uso en terapia. |
| LT2994465T (lt) | 2013-05-10 | 2018-10-10 | Karus Therapeutics Limited | Nauji histono deacetilazės inhibitoriai |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| RU2633266C2 (ru) * | 2015-07-02 | 2017-10-11 | Рауф Ашрафович Ашрафов | Способ моделирования карциноидного синдрома |
| CN105367479A (zh) * | 2015-11-16 | 2016-03-02 | 青岛大学 | 一种组蛋白去乙酰酶抑制剂2-(1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1氢-吲哚-3-基-n-(2-(羟氨基)-2-酮乙基)乙酰胺及其制备方法和应用 |
| CN109928909A (zh) * | 2019-04-02 | 2019-06-25 | 南华大学 | 具有抗抑郁活性化合物及其制备方法 |
| CN120136763B (zh) * | 2025-03-13 | 2025-10-10 | 遵义医科大学 | 一种c-3苄基化吲哚类化合物、制备方法及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0887348A1 (en) * | 1997-06-25 | 1998-12-30 | Boehringer Mannheim Italia S.p.A. | Bis-Indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them |
| IT1317925B1 (it) * | 2000-11-03 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Bis-eterocicli ad attivita' antitumorale e chemosensibilizzante. |
| WO2003032982A1 (en) | 2001-10-19 | 2003-04-24 | Transtech Pharma, Inc. | Bis-heteroaryl alkanes as therapeutic agents |
| JP4790594B2 (ja) * | 2003-02-25 | 2011-10-12 | トポターゲット ユーケー リミテッド | Ｈｄａｃインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物 |
-
2006
- 2006-05-24 TW TW095118475A patent/TW200716545A/zh unknown
- 2006-05-31 JP JP2008515199A patent/JP2008542428A/ja not_active Withdrawn
- 2006-05-31 KR KR1020077029390A patent/KR20080029967A/ko not_active Ceased
- 2006-05-31 MX MX2007015274A patent/MX2007015274A/es not_active Application Discontinuation
- 2006-05-31 WO PCT/EP2006/062798 patent/WO2006131484A1/en not_active Ceased
- 2006-05-31 EA EA200702672A patent/EA013542B1/ru not_active IP Right Cessation
- 2006-05-31 AU AU2006256771A patent/AU2006256771A1/en not_active Abandoned
- 2006-05-31 EP EP06777259A patent/EP1891007A1/en not_active Withdrawn
- 2006-05-31 CA CA002607337A patent/CA2607337A1/en not_active Abandoned
- 2006-05-31 BR BRPI0612542-5A patent/BRPI0612542A2/pt not_active IP Right Cessation
- 2006-05-31 CN CNA2006800205522A patent/CN101193861A/zh active Pending
- 2006-05-31 US US11/917,065 patent/US8053460B2/en not_active Expired - Fee Related
- 2006-06-08 AR ARP060102385A patent/AR053891A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101715343B (zh) | 流感治疗药 | |
| TWI344843B (en) | Prodrugs of piperazine and substituted piperidine antiviral agents | |
| AU2014224111B2 (en) | Positively charged water-soluble prodrugs of 1H-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates | |
| CN104703595B (zh) | 涉及血管破坏剂和靶向缺氧的药剂的组合疗法 | |
| EP1416928A2 (en) | N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents | |
| JP2013541519A (ja) | 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体 | |
| JP2013545730A5 (enExample) | ||
| JP2006524662A5 (enExample) | ||
| BR112013001553A2 (pt) | Métodos e compostos para tratar infecções por vírus paramyxoviridae | |
| CN1181014A (zh) | 抑制病毒和癌生长的含n-膦酰甘氨酸衍生物的药物组合物 | |
| JP2008542428A5 (enExample) | ||
| EP2555766A2 (en) | Antimetastatic compounds | |
| CN1107677C (zh) | 喜树碱衍生物和制备方法及其作为抗肿瘤剂的应用 | |
| CN115667209A (zh) | 用于治疗sars的化合物 | |
| CN101050213A (zh) | 9－脂肪氨基取代小檗碱衍生物及其制备方法与作为抗癌药物的应用 | |
| JP2009501234A (ja) | ヒドロキノンアンサマイシンを用いた治療方法 | |
| CN1794986A (zh) | 治疗癌症的新方法 | |
| EP3880684B1 (en) | In-flow photooxygenation of aminothienopyridinones generates novel ptp4a3 phosphatase inhibitors | |
| JPWO2021093839A5 (enExample) | ||
| CN102101858B (zh) | 雷莫司琼衍生物及其制备方法和用途 | |
| EP2094265B1 (en) | Pyrroloy[1,2-a]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents | |
| CN1917867A (zh) | 具有抗肿瘤活性的化合物 | |
| TWI908780B (zh) | 稠合二環類衍生物、其製備方法及其在醫藥上的應用 | |
| JP2011219384A (ja) | グリオキサラーゼｉ阻害剤 | |
| JP7260912B2 (ja) | リファガールの類縁体、及びリファガール又はその類縁体を含む多標的キナーゼ阻害剤 |